ストックスクリーナーアプリを入手
5.39
4.05%
0.21
アフターアワーズ：
5.34
-0.05
-0.93%
前日終値:
$5.18
開ける：
$5.12
24時間の取引高:
994.06K
Relative Volume:
0.46
時価総額：
$184.98M
収益：
-
当期純損益:
$-42.05M
株価収益率:
-0.9074
EPS:
-5.94
ネットキャッシュフロー:
$-35.26M
1週間 パフォーマンス:
-9.87%
1か月 パフォーマンス:
+133.33%
6か月 パフォーマンス:
+123.65%
1年 パフォーマンス:
+196.15%
1日の値動き範囲:
$5.01
$5.41
1週間の範囲:
$4.91
$5.98
52週間の値動き範囲:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
名前
Protara Therapeutics Inc
セクター
電話
646-844-0337
住所
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.39 | 184.98M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-10 | 再開されました | Guggenheim | Buy |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-17 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-07-29 | 開始されました | Guggenheim | Buy |
Protara Therapeutics Inc (TARA) 最新ニュース
Velan Capital Investment Management LP Increases Stake in Protara Therapeutics Inc - GuruFocus.com
Flatiron-based drug company raises $100M for cancer treatment - Crain's New York Business
Protara Therapeutics: Rising From The Ashes (NASDAQ:TARA) - Seeking Alpha
Protara Therapeutics Raises $100M in Stock Offering - TipRanks
Protara Announces Closing of $100 Million Public Offering - GlobeNewswire
SEC Form 424B5 filed by Protara Therapeutics Inc. - Quantisnow
Protara Therapeutics Secures Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Therapeutics: Carving New Roads In Bladder Cancer (TARA) - Seeking Alpha
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst - Seeking Alpha
Protara announces public offering to fund clinical programs By Investing.com - Investing.com Canada
Protara Therapeutics drops 6%, prices $100M offering - MSN
Protara Announces Pricing of $100 Million Public Offering - citybiz
Protara Therapeutics Launches Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Announces Proposed Public Offering - The Manila Times
Protara announces public offering to fund clinical programs - Investing.com
Protara Therapeutics Launches Public Offering to Advance TARA-002 Clinical Development - StockTitan
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes - MSN
HC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA) - Defense World
Protara Therapeutics (STU:1KPA) Enterprise Value : €42.66 Mil (As of Dec. 07, 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Guggenheim - MarketBeat
Protara Therapeutics' (TARA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most - Yahoo Finance
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy - Yahoo Finance
Protara, CG Oncology Tout Promising Bladder Cancer Outcomes - BioSpace
Protera Therapeutics stock remains Buy-rated after promising TARA-002 Phase II results - Investing.com Canada
Protara cell therapy impresses in non-muscle invasive bladder cancer - FirstWord Pharma
TARA stock soars to 52-week high, touches $9.45 amid robust gains - Investing.com Australia
TARA-002 shows promise in bladder cancer trial By Investing.com - Investing.com South Africa
Protara shares spike after cell therapy shows high response rate, no severe side effects in bladder cancer trial - Fierce Biotech
Protara Therapeutics (FRA:1KPA) EV-to-Revenue : (As of Dec. 05, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 55.72 (As of Dec. 05, 2024) - GuruFocus.com
Stock market news: Arcadia Biosciences +186.66%, Protara Therapeutics +101.69% among top gainers during mid day trading - Business Upturn
Protara, CG climb bladder ladder with SUO cancer findings - BioWorld Online
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday? - Benzinga
Stock market today: Arcadia Biosciences +153.62%, Protara Therapeutics +133.20% among top gainers in early trading - Business Upturn
Protara Therapeutics Reports Promising Phase 2 Trial Results - TipRanks
Protara Therapeutics shares surge on positive trial results - Investing.com
Protara Therapeutics shares surge on positive trial results By Investing.com - Investing.com UK
Protara Therapeutics, Inc. Announces Positive Results from the Ongoing Phase 2 Advanced Advanced-2 Trial of TARA-002 in Patients with NMIBC - Marketscreener.com
Protara Therapeutics Shares Soar on Positive Data for Bladder Cancer Treatment Trials - MarketWatch
Adf Group Inc Sv (DRX-T) QuotePress Release - The Globe and Mail
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - The Manila Times
Protara's TARA-002 Shows Breakthrough 72% Response Rate in Bladder Cancer Trial Results - StockTitan
TARAProtara Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Protara Therapeutics to Present Phase 2 Bladder Cancer Trial Data at Key Oncology Meeting - StockTitan
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Protara Therapeutics (FRA:1KPA) 3-Year FCF Growth Rate : 0.40% (As of Sep. 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) EV-to-Revenue : (As of Nov. 26, 2024) - GuruFocus.com
Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation - Simply Wall St
Protara Therapeutics Inc (TARA) 財務データ
収益
当期純利益
現金流量
EPS
Protara Therapeutics Inc (TARA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Sep 11 '24 |
Sale |
1.71 |
32,600 |
55,880 |
51,500 |
| Opaleye Management Inc. | 10% Owner |
Sep 09 '24 |
Sale |
1.89 |
36,492 |
69,141 |
54,600 |
| Opaleye Management Inc. | 10% Owner |
Sep 10 '24 |
Sale |
1.77 |
25,500 |
45,110 |
53,100 |
| Opaleye Management Inc. | 10% Owner |
Jul 16 '24 |
Sale |
2.44 |
11,396 |
27,828 |
56,500 |
| Opaleye Management Inc. | 10% Owner |
Jul 11 '24 |
Sale |
2.40 |
47,993 |
115,346 |
60,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 10 '24 |
Sale |
2.31 |
18,061 |
41,685 |
75,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 09 '24 |
Sale |
2.21 |
8,497 |
18,811 |
80,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 01 '24 |
Sale |
2.12 |
8,288 |
17,598 |
87,500 |
| Opaleye Management Inc. | 10% Owner |
Jun 27 '24 |
Sale |
2.26 |
46,574 |
105,169 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 28 '24 |
Sale |
2.07 |
17,994 |
37,334 |
85,000 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):